EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient

Malvezzi, 2012, European cancer mortality predictions for the year 2012, Ann. Oncol., 23, 1044, 10.1093/annonc/mds024 Cardarella, 2012, The introduction of systematic genomic testing for patients with non-small-cell lung cancer, J. Thorac. Oncol., 7, 1767, 10.1097/JTO.0b013e3182745bcb Ihle, 2012, Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome, J. Natl. Cancer Inst., 104, 228, 10.1093/jnci/djr523 Wen, 2014, Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma, Medicine (Baltimore), 93, e296, 10.1097/MD.0000000000000296 Fiala, 2013, The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer, Cancer Genet., 206, 26, 10.1016/j.cancergen.2012.12.003 Choughule, 2014, Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer, Br. J. Cancer, 111, 2203, 10.1038/bjc.2014.401 Bergethon, 2012, ROS1 rearrangements define a unique molecular class of lung cancers, J. Clin. Oncol., 30, 863, 10.1200/JCO.2011.35.6345 Rimkunas, 2012, Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion, Clin. Cancer Res., 18, 4449, 10.1158/1078-0432.CCR-11-3351 Takeuchi, 2012, RET,ROS1 and ALK fusions in lung cancer, Nat. Med., 18, 378, 10.1038/nm.2658 Zhu, 2015, Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis, Transl. Lung Cancer Res., 4, 300 Davies, 2012, Identifying and targeting ROS1 gene fusions in non-small cell lung cancer, Clin. Cancer Res., 18, 4570, 10.1158/1078-0432.CCR-12-0550 Shaw, 2015, Crizotinib in ROS1-rearranged non-small-cell lung cancer, N. Engl. J. Med., 372, 683, 10.1056/NEJMc1415359 Takeuchi, 2012, RET, ROS1 and ALK fusions in lung cancer, Nat. Med., 18, 378, 10.1038/nm.2658 Sun, 2010, Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases, J. Clin. Oncol., 28, 4616, 10.1200/JCO.2010.29.6038 Yoshida, 2013, ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases, Am. J. Surg. Pathol., 37, 554, 10.1097/PAS.0b013e3182758fe6 Shaw, 2014, Crizotinib in ROS1-rearranged non-small-cell lung cancer, N. Engl. J. Med., 371, 1963, 10.1056/NEJMoa1406766 Yang, 2014, Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation, Clin. Cancer Res., 20, 1383, 10.1158/1078-0432.CCR-13-0699 Won, 2015, Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor, Ann. Oncol., 26, 348, 10.1093/annonc/mdu530 Baldi, 2014, Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells, Lung Cancer, 86, 291, 10.1016/j.lungcan.2014.09.011 Campos-Gomez, 2015, Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report, Int. J. Biol. Markers, 30, e254, 10.5301/jbm.5000127 Devarakonda, 2015, Genomic alterations in lung adenocarcinoma, Lancet Oncol., 16, e342, 10.1016/S1470-2045(15)00077-7 Brugger, 2011, Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer, J. Clin. Oncol., 29, 4113, 10.1200/JCO.2010.31.8162 Mao, 2010, KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies, Lung Cancer., 69, 272, 10.1016/j.lungcan.2009.11.020 Linardou, 2008, Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer, Lancet Oncol., 9, 962, 10.1016/S1470-2045(08)70206-7 Benesova, 2010, Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors, Anticancer Res., 30, 1667